

## Prescient Therapeutics Opens Share Purchase Plan

### Key Highlights:

- Prescient Therapeutics opens Share Purchase Plan (SPP) to raise up to \$7.0M (before costs).
- Eligible shareholders will be able to acquire new shares at an issue price of \$0.04 (4 cents) per share, representing a 16.7% discount to 15-day VWAP, without incurring brokerage or transaction fees.
- Funds raised will be used to advance PTX-100 through Phase 2 clinical development toward potential regulatory approval.

**MELBOURNE Australia, 2 July 2025** – Prescient Therapeutics (ASX: PTX) (**'PTX** or the **Company**), an ASX-listed biotechnology company developing targeted and personalised medicines for cancer, is pleased to advise that the Share Purchase Plan (**SPP**) announced 1 July 2025, [Announcement](#), opens today.

Under the SPP new fully paid ordinary shares will be issued at \$0.040 per share, equivalent to a 16.7% discount to the volume weighted average price (**VWAP**) over the 15 trading days before the date the SPP was announced, and a 9.1% discount to the closing price on 30 June 2025.

The Company will offer Eligible Shareholders who were registered shareholders as at 7:00pm (AEST) on Monday, 30th June 2025 (**Record Date**) the opportunity to apply for up to A\$30,000 of new fully paid ordinary shares (**New Shares**) in the Company under the SPP. The SPP is expected to remain open until the close of business 15 July 2025. Full details of the SPP will be set out in the SPP Offer Booklet which is expected dispatched to eligible shareholders today. A copy of the SPP Offer Booklet is attached to this announcement.

Shareholders can request an electronic copy of their personalised Share Purchase Plan application form be emailed to them as soon as available:

<https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>

Reach Markets are the advisers managing the Share Purchase Plan and can be contacted on [1300 805 795](tel:1300805795) or via [advisers@reachmarkets.com.au](mailto:advisers@reachmarkets.com.au)

### Join a shareholder briefing

Join the CEO of PTX James McDonnell for a live and interactive shareholder briefing on Friday, 4th July 11am (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate.

Register here: <https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

---

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

### For more information please contact:

#### Company enquiries

James McDonnell  
CEO  
Prescient Therapeutics  
[james.mcdonnell@ptxtherapeutics.com](mailto:james.mcdonnell@ptxtherapeutics.com)  
[www.ptxtherapeutics.com](http://www.ptxtherapeutics.com)

#### Media enquiries

Reach Markets  
1300 805 795  
[ir@reachmarkets.com.au](mailto:ir@reachmarkets.com.au)

#### Corporate enquiries

Christian Riedel, CFA  
0480187650  
[christian.riedel@reachmarkets.com.au](mailto:christian.riedel@reachmarkets.com.au)

### About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

#### Targeted Therapy

**PTX-100:** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) has completed the first dose in a patient and expects to enrol up to 40 patients in the phase 2a part of the trial.

For personal use only

## Cell Therapy Platforms

**CellPryme-M:** Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

**CellPryme-A:** CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com) or connect with us via [LinkedIn](#).

## Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other

For personal use only

factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.



1 July 2025

Dear Shareholder

## Share purchase plan

On behalf of the Board, I am pleased to offer you the opportunity to apply for new shares in Prescient Therapeutics Limited, (ASX: PTX) (**Prescient** or **Company**) under a share purchase plan (**SPP**).

The SPP allows Eligible Shareholders the opportunity to subscribe for up to \$30,000 worth of new shares without paying brokerage or other transaction costs.

We have deliberately chosen to offer you, our shareholders, an opportunity to participate in this exciting stage of Prescient's journey, as we advance through our Phase 2 trials for PTX-100.

In the last six months, Prescient has submitted and received Fast Track Designation from the FDA for PTX-100, activated the Phase 2a PTX-100 clinical trial with site activations and the first patient has been enrolled. Our focus remains on the implementation of this trial.

There is a tangible opportunity for us to move into a US\$1.8 billion T Cell Lymphoma target market, with several significant near-term milestones. Given Phase 1b results and FDA designations we have received, we are working towards making Prescient one of Australia's biotech success stories and improving the lives of many.

The SPP is available to shareholders who were on the Company register at 7.00pm (AEST) on 30 June 2025 (**Record Date**) and have a registered address in Australia or New Zealand (**Eligible Shareholders**).

The Company is seeking to raise \$7 million under the SPP, however the Company reserves the right to raise more or less than this amount at its absolute discretion. The Board also reserves the right to close the Offer early or extend the Offer at its absolute discretion.

The SPP gives Eligible Shareholders the opportunity to purchase additional fully paid ordinary shares in Prescient Therapeutics Limited at \$0.040 per share, which represents a discount of 9.1% to the closing price on 30 June 2025, and a discount of 16.7% to the 15-day VWAP. There are no transaction costs or brokerage costs to participating shareholders.

The proceeds from the SPP will support the advancement of the Company's first-in-class targeted cancer therapy PTX-100, specifically by funding continued Phase 2 clinical development. The Company is working to progress this potential therapy through clinical trials and toward regulatory approval and access for patients with significant unmet medical needs.

Included with this letter is the following material which aims to address any questions you may have about the SPP:

- an investment overview, which includes details on pricing, the timetable, intended use of funds and key risks of an investment in the Company;
- SPP terms.

The SPP will close on Tuesday, 15th July 2025 at 5.00pm (AEST). Acceptances and payment must be received by our registry, Automic, by the closing date. The Company reserves its right to close the SPP early.

## How to participate in the SPP Offer

The SPP is an offer to shareholders who were registered holders of fully paid ordinary shares in Prescient Therapeutics (Shares) at 7.00pm (AEST) on 30 June 2025 (Record Date) with a registered address in Australia or New Zealand (Eligible Shareholders). All Eligible Shareholders have the opportunity to participate in the SPP.

Shareholders may request an electronic copy of their personalised Share Purchase Plan Application Form here: <https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>

The SPP opens on 2 July 2025, and will close on Tuesday, 15th July 2025 at 5.00pm (AEST). Late applications may be accepted or rejected in the absolute discretion of the Company. The Company also reserves the right to vary the Closing Date without prior notice subject to the Corporations Act and the ASX Listing Rules.

The Company has appointed Reach Markets Pty Ltd as Lead Manager to the Share Purchase Plan. If you have any questions, please contact them on [advisers@reachmarkets.com.au](mailto:advisers@reachmarkets.com.au) or by calling 1300 805 795.

**Join a shareholder briefing**

Join CEO James McDonnell for an upcoming live and interactive shareholder briefing on behalf of the Board where he will discuss the Share Purchase Plan and use of funds.

Register for a session here:

<https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

The Board encourages you to consider this opportunity and thanks you for your continued support.

Yours faithfully,

**Dr James Campbell**  
**Non-Executive Chairman**  
**Prescient Therapeutics**

**PTX investment overview**

**Offer details**

<b>Issue Price</b>	\$0.040 per share		
<b>Record Date</b>	7.00pm (AEST) on 30 June 2025		
<b>Closing Date</b>	5.00pm (AEST) on 15 July 2025		
<b>Allotment Date</b>	22 July 2025		
<b>Quotation Date</b>	23 July 2025		
<b>Application Amount</b>	Minimum of \$5,000 ( <b>Minimum Application Amount</b> ) with staged increments detailed below up to a maximum of \$30,000.		
	Option	Value	Number of New Shares
	A	\$30,000	750,000
	B	\$20,000	500,000
	C	\$15,000	375,000
	D	\$10,000	250,000
	E	\$5,000	125,000

**Intended use of funds**

The proceeds from the SPP will support the advancement of the Company’s first-in-class cancer treatment, specifically by funding the continued Phase 2 clinical development of its targeted therapy, PTX-100. The Company is working to progress this potential therapy through clinical trials and toward regulatory approval and access for patients with significant unmet medical needs. Funds will also go towards general working capital and costs of the offer.

**Risks**

Before making an investment decision, you should read the SPP terms set out below. PTX considers that the major risks of an investment in PTX include:

**technical risks** - the inherent nature of research and development is uncertain. There are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. The Company is mitigating this risk where reasonably possible through diversification of its product pipeline, undertaking rigorous scientific review during the development process, and working with reputable and capable partners and service providers;

**future funding risks** - whilst the Directors believe that the funds raised through the SPP may be sufficient for the Company’s short-term objectives, the Company’s ability to continue on a going concern basis will depend upon securing income through licence or other agreements. Furthermore, there is risk that the Company may require substantial additional financing in the future to sufficiently fund its operations, research and development;

For personal use only

**regulatory and licensing risks** - if the Company does not obtain the necessary regulatory approvals it may be unable to commercialise its products. Even if it receives regulatory approval for any product candidates, profitability will depend on its ability to generate revenues from the sale of its products or the licensing of its technology;

**success of future trials** - future clinical trials of the Company's product candidates may not show sufficient safety or efficacy to obtain requisite regulatory approvals for commercial sale;

**commercialisation of products** - the Company's ability to achieve profitability is dependent on a number of factors including its ability to initiate and complete successful clinical trials and obtain regulatory approval for its products and successfully commercialise those products. There is no guarantee that the Company's products will be commercially successful;

**competition** – the biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. To compete successfully the Company must deliver to the market cost effective products that meet important medical needs;

**risk of delay** – the Company may experience delay in achieving a number of critical milestones, securing further commercial partners, development of manufacturing processes, completion of clinical trials, obtaining regulatory approval (to commence sales) or reimbursement approvals (for sales growth), product launch and sales in one or more jurisdictions. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments;

**dependence on commercial partners and future licence arrangements** - there is no guarantee that the Company will be able to find suitable industry partners that it can negotiate attractive commercial terms for future licence agreements for new or its existing products. The success of the Company's partnering arrangements may depend on resources devoted to them by itself or its industry partners. Collaborative agreements may be terminable by the Company's partners. Non-performance, suspension or termination of relevant agreements is likely to have a material and adverse impact on the Company's business, financial condition and results of operations;

**reimbursement** - in many territories, products such as those being developed by the Company, must follow a formal reimbursement process in order to be commercially successful. The availability and timing of reimbursement may have an impact upon the uptake and profitability of products in some jurisdictions;

**asset impairment value** - the Company has a significant amount of intangible assets recorded on its balance sheet. The Company annually tests the carrying value of these intangible assets for impairment. The estimates and assumptions about results of operations and cash flows made in connection with impairment testing could differ from future actual results of operations and cash flows;

**reliance on key personnel** - the Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including those employed on a contractual basis. The loss of the services of such personnel or the reduced ability to recruit additional personnel could have an adverse effect on the performance of the Company;

**intellectual property** - the Company's ability to leverage its innovation and expertise is dependent on its ability to protect its intellectual property and any improvements to it; and

**IT system failure and cyber security risks** - any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet and data network failures, and natural disasters. The Company is committed to preventing and reducing cyber security risks through outsourced IT management to a reputable services provider. In addition, the Company has an insurance policy covering IT and cyber security.

**Past performance is not necessarily a guide to future performance of the Company.**

## PTX Share purchase plan terms

---

### How do I accept

To participate, you should pay the Application Amount via BPAY® so that payment is received by **5.00pm (AEST) on 15 July 2025**. EFT is also available for overseas holders and for those who are otherwise unable to use BPAY.

BPAY and EFT instructions are set out on the application form. You do not need to return your application form. If paying via BPAY, please make sure you use the specific biller code and reference number on your personalised application form. If paying via EFT, please ensure you use the unique entitlement reference number within the EFT section as your description in order to allow your payment to be allocated to your holding. Your financial institution may implement earlier cut-off times for electronic payment. You should take this into consideration when making payment.

Eligible Shareholders who would like to request an electronic copy of their personalised SPP Offer Application Forms can do so by registering here - <https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>.

Funds received for applications by BPAY or EFT will be regarded as applications for the maximum number of shares that those funds will pay for in full.

**Importantly, while participation in the plan is optional, once applications are submitted, they cannot be withdrawn.**

**The Company's market price may vary at any time during the offer period and the Company's shares may trade at a price that is lower than the Issue Price.**

**By accepting the SPP offer, you accept the risk that the market price of the Company's shares may fall below the Issue Price between the date of this offer and the Allotment Date, in which case you may have been able to buy the Shares at a lower price than the Issue Price.**

**By making an application, you represent to the Company the matters set out under the heading 'Your representations' in these terms and in the application form.**

### How many shares

Eligible Shareholders receive the number of shares equal to the Application Amount (subject to any scale-back) divided by the Issue Price. Fractions will be rounded down, and the difference (being any amount less than the Issue Price) may be retained by the Company.

The Issue Price does not exceed the limit prescribed by the ASX Listing Rules and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**ASIC Instrument 2019/547**).

Shares issued under the SPP may be sold or transferred on ASX at any time after the Quotation Date.

### Eligibility to participate

Participation in the SPP is optional. The offer is open to all shareholders with a registered address in Australia or New Zealand as at the Record Date.

#### *Multiple holdings*

If you are the only registered holder of Company shares, but you receive more than one offer under the SPP (for example, due to multiple registered holdings), you may only apply in total for a maximum of \$30,000 worth of shares.

#### *Joint holders*

If you are a joint holder of Company shares, that holding is considered to be a single registered holding for the purpose of the SPP. You are entitled to participate in the SPP for that single holding only. If you are a joint holder and you receive more than one offer under the SPP, you may only apply in total for a maximum of \$30,000 worth of shares.

### *Trustee or nominee*

If you are noted on the Company's share register as a trustee or nominee for a named beneficiary, you may only apply for one maximum parcel of shares for each named beneficiary. If the Company's share registry does not record a named beneficiary for your trustee or nominee holding, the rules for multiple single holdings apply.

### *Custodians*

If you are a custodian within the definition of 'custodian' in ASIC Instrument 2019/547 (as varied) and hold Company shares for one or more persons (each a **Participating Beneficiary**), or for another custodian of Company shares, you may apply for up to a maximum of \$30,000 worth of shares for each Participating Beneficiary, subject to providing the Company a 'custodian certificate' in addition to the application form, which certifies matters required by ASIC Instrument 2019/547 (as varied).

Please contact the share registry via email on [corporate.actions@automicgroup.com.au](mailto:corporate.actions@automicgroup.com.au) to obtain the custodian certificate.

### **Directors**

Directors of the Company who are Eligible Shareholders may participate in the SPP.

### **Scale-back**

The Company may, in its absolute discretion, scale-back applications under the SPP.

Factors that the Company may take into account in determining any scale-back include:

- compliance with regulatory requirements, including the considerations raised by the ASX in its public consultation paper dated 5 April 2022 (**Consultation Paper**) as it applies to appropriate scale-back considerations which the Company may consider in an SPP (section 2.1.1 of the Consultation Paper);
- the date on which a shareholder made its application for shares;
- the amount applied for by each shareholder;
- the number of shares held at the Record Date; and

- if the shareholder remains on the register at the Closing Date.

The Company may scale-back applications below the Minimum Application Amount. Scale-back decisions are made by the board and are final.

If a scale-back occurs, the difference between the value of the shares allotted and the Application Amount paid to the Company (only where the amount is greater than the Issue Price) will be refunded by cheque and mailed to you as soon as practicable following the Allotment Date. Any scale-back will be announced on the Allotment Date. No interest will be paid on any Application Amount paid or refunded.

The ability to scale-back applications under the terms of this document remains available to the Company, including in circumstances where the Company has elected to close the offer early and any such scale-back will not prevent the Company from undertaking a subsequent placement.

### **ASX quotation**

After shares are issued and allotted under the SPP, the Company will apply to ASX for quotation of the shares on the Official List and send an allotment notice to each Eligible Shareholder's registered address.

### **No costs**

Eligible Shareholders may subscribe without incurring brokerage costs, commission or other transaction costs.

### **Who is the Lead Manager?**

The Lead Manager for the SPP and any follow-on placement is Reach Markets Pty Ltd ACN 145 312 232 (**Reach**).

Reach can be contacted on 1300 80 57 95 or via email on [advisers@reachmarkets.com.au](mailto:advisers@reachmarkets.com.au).

The Company will pay Reach a 6% fee on funds actually raised from the SPP (which may include any shortfall/follow-on placement, if requested by the Company). In addition, Reach is to receive one call option for every 20 ordinary shares issued, with an exercise price of \$0.06 (6 cents), expiring 4 years following the issue date. These options are to be issued 14 days following the settlement of the SPP.

## Privacy

Potential Applicants who apply for New Securities will provide 'personal information' (within the meaning given to that term in the Privacy Act) to the Company, the Lead Manager and the Share Registry. By applying for New Securities under an Offer, an Applicant will be taken to have consented to the Company, the Lead Manager and the Share Registry collecting, holding and using the Applicant's personal information in order to assess their Application, process the Applications, service their needs as a Shareholder, provide facilities and services that the Applicant request, and carry out appropriate administrative functions. Corporate and taxation laws require the Company to collect some personal information. Applicants who do not provide the information requested may not have their Application processed efficiently, or at all.

Reach's Privacy Policy can be viewed here - <https://reachmarkets.com.au/privacy-reach/> along with their Financial Services Guide, available here - <https://reachmarkets.com.au/financial-services-guide>

Automic's Privacy Policy can be viewed here - <https://www.automicgroup.com.au/privacy-policy/>

## The Company's rights

The Company may reject any application for shares under the SPP if:

- it considers that the application does not comply with these terms;
- you are not an Eligible Shareholder; or
- there are grounds for believing that the applicant is not acting in good faith.

The Company may modify, suspend or cancel the SPP at any time. This includes closing the SPP early or extending the Offer as it sees fit. If the Company does this it will notify ASX. If the SPP is cancelled the Application Amount will be refunded without interest. Neither the Company nor the board accepts or assumes any liability to shareholders because of the variation, suspension or termination of SPP.

The Company may settle, at its discretion in any manner it deems fit, any anomalies or disputes in connection with the SPP and that decision is conclusive and binding on all applicants. The

Company reserves the right to waive strict compliance with these terms.

The Company reserves the right to run a follow-on placement to exempt investors on conclusion of the SPP should there be sufficient demand.

## Your representations

By making a BPAY or EFT payment, you:

- certify to the Company that you are an Eligible Shareholder;
- authorise the Company (and its officers and agents) to correct any error in, or omission from, your application form;
- accept the risks of the delivery of any refund to you;
- acknowledge that the Company may at its discretion determine that your application form is valid, even if the application form is invalid;
- confirm you have read and accept all the included risks associated with this offer;
- irrevocably and unconditionally agree to these terms; and
- acknowledge that the Company is not liable for any exercise of its discretions referred to in these terms.

## Other information

The Offer is non renounceable, which means that you cannot transfer your right to purchase shares under the SPP to anyone else. Shares issued under the SPP will rank equally in all respects with existing fully paid shares.

This document is not an offer of securities in any place outside Australia or New Zealand and does not take into account your individual investment objectives, financial situation or particular needs. An investment in the Company is speculative. Therefore, you should obtain independent financial and taxation advice before making an investment decision